Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
Microwave Ablation Controls Breast Metastasis for Three Years
This case report and review of the literature describes ultrasound-guided microwave ablation in a 59-year-old female with metastatic breast …
A single session of microwave ablation kept a breast cancer metastasis under control for three years with no major side effects.
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
A Rare Tumor That Fooled Doctors at Every Step — Until One Test Changed Everything
This case report and literature review describes a 64-year-old male with thoracic SMARCA4-deficient undifferentiated tumor initially misdiag…
A rare chest tumor mimicking lung cancer was misdiagnosed until a specific genetic test revealed the true cause, proving one marker can prev…
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
Why Your Lung Cancer Risk Is Not The Same As Your Neighbor's
This retrospective cohort study evaluated gene expression programs in early-stage (IA/IB) lung adenocarcinoma patients.
Hidden immune signals in early lung cancer act like a weather forecast, predicting who will stay well and who faces a quick return of the di…
NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
A Hidden Cell Type in Lung Cancer May Hold a New Target
This preclinical and computational study analyzed public databases and performed in vitro experiments to evaluate cancer-associated fibrobla…
A hidden protein in support cells around lung tumors may drive cancer growth, pointing to a new treatment target for lung adenocarcinoma.
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
New Drug Combo Helps Some Lung Cancer Patients Live Longer
A single-arm, open-label phase Ib/II trial in 52 patients with pretreated stage IIIB/IV NSCLC adenocarcinoma found a 6-month progression-fre…
A new drug pair safely extends life for some advanced lung cancer patients who previously tried immunotherapy or have high PD-L1 markers.
Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
A Simple Scan May Now Predict a Hidden Lung Cancer Danger Before Surgery
This cohort study evaluated a predictive nomogram combining spectral dual-layer detector CT radiomics, deep learning features, and pleural i…
Doctors may soon use artificial intelligence to find a hidden sign of aggressive lung cancer before a patient ever goes into the operating r…
AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
A Simple Blood Test Could Predict Your Lung Cancer Treatment Success
This preprint describes an observational cohort study involving 1,720 lung adenocarcinoma patients, with validation across additional cohort…
A new blood test score predicts which lung cancer patients will respond to immunotherapy, helping doctors avoid ineffective treatments for a…
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Undetectable baseline ctDNA significantly improves progression-free and overall survival in advanced NSCLC patients
Tumor DNA Levels Help Predict Outcomes in Lung Cancer Treatment
This meta-analysis of 2,107 patients evaluates the role of circulating tumor DNA (ctDNA) as a biomarker for outcomes in advanced NSCLC treat…
Testing for circulating tumor DNA may help doctors predict how well patients with advanced lung cancer respond to immunotherapy treatments.
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis shows sublobar resection linked to worse survival outcomes compared with lobectomy for early-stage non-small cell lung cancer patients
Sublobar resection shows mixed survival results for early lung cancer
This umbrella review of meta-analyses indicates sublobar resection carries higher risks for overall and disease-free survival in Stage I non…
An umbrella review found mixed survival results for sublobar resection versus lobectomy in early-stage non-small cell lung cancer.
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Immune checkpoint inhibitors before lung cancer surgery show acceptable safety profile
Immunotherapy before lung cancer surgery is safe, study finds
This meta-analysis of patients with resectable non-small cell lung cancer found that neoadjuvant or perioperative immune checkpoint inhibito…
A new analysis of 2,691 patients shows that immunotherapy before lung cancer surgery is feasible, but comes with specific surgical challenge…
Cutaneous immune-related adverse events associated with improved progression-free survival in non-small cell lung cancer
Skin reactions in lung cancer patients may signal longer life with certain treatments
This meta-analysis evaluated patients with non-small cell lung cancer receiving anti-PD-1, PD-L1, or chemotherapy. The analysis found that c…
A large review found that specific skin reactions linked to cancer drugs are connected to longer survival times for some lung cancer patient…
Perspective review on radiation therapy and cardiac toxicity in lung cancer
Radiation planning may help protect heart and immune system in lung cancer patients
This perspective review article synthesizes evidence on thoracic radiation therapy for locally advanced non-small cell lung cancer, focusing…
A perspective review suggests radiation planning techniques could spare the heart and immune system for lung cancer patients.
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Questions about Lung Adenocarcinoma
How does gene expression affect survival in early-stage lung adenocarcinoma?
Gene expression programs involving immune cells, stromal remodeling, and acylation modifications significantly predict survival and recurrence in early-stage lung adenocarcinoma.
Full answer →Can aumolertinib be used again after osimertinib causes lung problems?
Yes, aumolertinib (almonertinib) has been successfully used after osimertinib caused lung problems like interstitial lung disease, based on case reports.
Full answer →All Lung Adenocarcinoma Articles
- Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
- Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
- Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
- Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
- Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
- Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
- NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
- AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
- Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
- CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma